Synairgen (SNG)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

1.99p
   
  • Change Today:
    -0.21p
  • 52 Week High: 5.46
  • 52 Week Low: 1.81
  • Currency: UK Pounds
  • Shares Issued: 202.66m
  • Volume: 14,444,916
  • Market Cap: £4.04m
  • RiskGrade: 510
  • Beta: 0.17

Synairgen Overview

In the 1970s, Synairgen founder, British immunophysician Professor Sir Stephen Holgate, began investigating how respiratory viruses can cause serious illness, with the aim of translating these insights into effective clinical treatments. Joined by fellow University of Southampton professors Donna Davies and Ratko Djukanovic in the 1990s, together the three formed Synairgen in 2003 with the sole aim of bringing these advances to patients.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a n/a
Pr/Book 0.4  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Synairgen Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-19 n/a (4.79) (2.55)p n/a n/a n/a n/a 0.0%
31-Dec-20 n/a (17.73) (6.84)p n/a n/a n/a n/a 0.0%
31-Dec-21 n/a (57.86) (17.55)p n/a n/a n/a n/a 0.0%
31-Dec-22 n/a (20.09) (6.33)p n/a n/a n/a n/a 0.0%
31-Dec-23 n/a (9.66) (3.02)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Synairgen Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-24 n/a (7.00) (2.15)p n/a n/a n/a n/a 0.0%
31-Dec-25 n/a (4.00) (1.08)p n/a n/a n/a n/a 0.0%

Copyright © 2025 FactSet Research Systems Inc. All rights reserved.

Synairgen Company Announcements

Martin Murphy appointed as Non-Executive Director 16-Jan-2025 15:42 RNS
Result of General Meeting and Total Voting Rights 16-Jan-2025 15:42 RNS
£18m raised to fund Phase 2 INVENT clinical... 15-Jan-2025 17:37 RNS

Synairgen ShareCast News

Synairgen names Joseph Colliver as CFO 11-Oct-2023 ShareCast
Synairgen posts positive results for phase 2 tri... 04-Oct-2022 ShareCast
Synairgen unveils positive clinical trial data 07-Sep-2022 ShareCast

Synairgen Top Newspaper Links

AstraZeneca buys the rights to an asthma treatme... 13-Jun-2014 Daily Mail
AstraZeneca in new £138million asthma drug deal 13-Jun-2014 Express & Star

Latest Synairgen Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Synairgen Market Data

Currency UK Pounds
Share Price 1.99p
Change Today -0.21p
% Change -9.43 %
52 Week High 5.46
52 Week Low 1.81
Volume 14,444,916
Shares Issued 202.66m
Market Cap £4.04m
Beta 0.17
RiskGrade 510

Synairgen Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
73.25% above the market average73.25% above the market average73.25% above the market average73.25% above the market average73.25% above the market average
83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average83.33% above the sector average
Price Trend
85.11% below the market average85.11% below the market average85.11% below the market average85.11% below the market average85.11% below the market average
75.51% below the sector average75.51% below the sector average75.51% below the sector average75.51% below the sector average75.51% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 0
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 1
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Synairgen Dividends

No dividends found

Trades for 16-Jan-2025

Time Volume / Share Price
16:27 4,300 @ 1.90p
16:25 10,000 @ 1.90p
16:24 10,500 @ 1.90p
16:21 28,601 @ 2.07p
16:18 4,852 @ 1.90p

Synairgen Key Personnel

CEO Richard J Marsden

Top of Page